Acceleron Pharma Inc  

(Public, NASDAQ:XLRN)   Watch this stock  
Find more results for GEORGE A. NADER´┐Ż
+0.76 (1.77%)
After Hours: 43.62 -0.01 (-0.02%)
Dec 1, 4:52PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 42.02 - 43.97
52 week 20.00 - 48.50
Open 42.95
Vol / Avg. 274,339.00/233,888.00
Mkt cap 1.42B
P/E     -
Div/yield     -
EPS -1.56
Shares 33.25M
Beta     -
Inst. own 85%
Feb 29, 2016
Q4 2015 Acceleron Pharma Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Dec 1, 2015
Acceleron Pharma Inc at Piper Jaffray Healthcare Conference
Nov 11, 2015
Acceleron Pharma Inc at Credit Suisse Healthcare Conference
Nov 5, 2015
Acceleron Pharma Inc at Citi Global Healthcare Conference
Nov 4, 2015
Q3 2015 Acceleron Pharma Inc Earnings Release
Nov 4, 2015
Q3 2015 Acceleron Pharma Inc Earnings Call - Webcast
Oct 23, 2015
Acceleron Pharma Inc Research and Development Day
Sep 30, 2015
Acceleron Pharma Inc at Leerink Partners Rare Disease Roundtable
Sep 18, 2015
Acceleron Pharma Inc at Morgan Stanley Healthcare Conference
Sep 10, 2015
Acceleron Pharma Inc at Citi Biotech Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -285.39% -350.32%
Operating margin -351.70% -379.06%
EBITD margin - -337.25%
Return on average assets -29.18% -33.07%
Return on average equity -35.08% -47.88%
Employees 83 -
CDP Score - -


United States - Map
+1-617-6499200 (Phone)
+1-617-6499988 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Acceleron Pharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic candidates that are based on the mechanisms that the human body uses to regulate the growth and repair of its cells and tissues. The Company's research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-b) protein superfamily. By combining its discovery and development know-how, including its knowledge of the TGF-b superfamily, and its internal protein engineering and manufacturing capabilities, the Company has built a discovery and development platform that has generated therapeutic candidates with new mechanisms of action. The Company has four internally discovered therapeutic candidates that are in clinical trials.

Officers and directors

Francois Nader M.D. Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
John L. Knopf Ph.D. President, Chief Executive Officer, Director
Age: 62
Bio & Compensation  - Reuters
Kevin F. McLaughlin Chief Financial Officer, Senior Vice President, Treasurer
Age: 58
Bio & Compensation  - Reuters
Steven D. Ertel Chief Operating Officer, Executive Vice President
Age: 45
Bio & Compensation  - Reuters
Matthew L. Sherman M.D. Executive Vice President and Chief Medical Officer
Age: 56
Bio & Compensation  - Reuters
Ravindra Kumar Ph.D Chief Scientific Officer, Vice President
Age: 55
Bio & Compensation  - Reuters
John D. Quisel J.D., Ph.D. Vice President, General Counsel, Secretary
Age: 43
Bio & Compensation  - Reuters
Terrence C. Kearney Director
Age: 60
Bio & Compensation  - Reuters
Jean M. George Independent Director
Age: 57
Bio & Compensation  - Reuters
George S. Golumbeski Ph.D. Independent Director
Age: 57
Bio & Compensation  - Reuters